Patient and disease characteristics
| Variables . | Haplo-HSCT . | ≤5/8 HLA-matched UCB . | 6-8/8 HLA-matched UCB . | P value comparing haplo- to UCB . | |
|---|---|---|---|---|---|
| ≤5/8 . | 6-8/8 . | ||||
| Number of subjects | 375 | 188 | 145 | ||
| Age, y | <.001 | <.001 | |||
| ≤16 | 67 (18%) | 70 (37%) | 84 (58%) | ||
| 17 to 29 | 132 (35%) | 61 (32%) | 26 (18%) | ||
| 30 to 39 | 75 (20%) | 34 (18%) | 21 (15%) | ||
| 40 to 49 | 101 (27%) | 23 (12%) | 14 (10%) | ||
| Sex | .13 | .99 | |||
| Male | 202 (54%) | 114 (61%) | 78 (54%) | ||
| Female | 173 (46%) | 74 (39%) | 67 (46%) | ||
| Race | .84 | .06 | |||
| Caucasian | 235 (63%) | 113 (60%) | 100 (69%) | ||
| Non-Caucasian | 109 (29%) | 58 (31%) | 28 (19%) | ||
| Not reported | 31 (8%) | 17 (9%) | 17 (12%) | ||
| Performance score | <.0001 | .31 | |||
| 90 to 100 | 235 (63%) | 150 (80%) | 101 (70%) | ||
| ≤80 | 132 (35%) | 37 (20%) | 42 (29%) | ||
| Not reported | 8 (2%) | 1 (<1%) | 2 (1%) | ||
| Comorbidity index | .20 | <.0001 | |||
| ≤2 | 237 (63%) | 129 (69%) | 117 (81%) | ||
| ≥3 | 138 (37%) | 59 (31%) | 28 (19%) | ||
| Recipient CMV serostatus | .74 | .65 | |||
| Negative | 119 (32%) | 57 (30%) | 52 (36%) | ||
| Positive | 254 (68%) | 129 (69%) | 92 (63%) | ||
| Not reported | 2 (<1%) | 2 (1%) | 1 (<1%) | ||
| Disease | .003 | .002 | |||
| AML | 193 (52%) | 72 (38%) | 53 (37%) | ||
| ALL | 182 (49%) | 116 (62%) | 92 (63%) | ||
| Disease status | .02 | .002 | |||
| 1st CR | 233 (62%) | 98 (52%) | 68 (47%) | ||
| 2nd CR | 142 (38%) | 90 (48%) | 77 (53%) | ||
| Disease risk index | .17 | .003 | |||
| Low/intermediate | 280 (75%) | 130 (70%) | 89 (62%) | ||
| High/very high | 95 (25%) | 57 (30%) | 56 (39%) | ||
| Cytogenetic risk | .002 | .06 | |||
| Favorable | 79 (21%) | 61 (32%) | 44 (30%) | ||
| Intermediate | 116 (31%) | 55 (29%) | 48 (33%) | ||
| Poor | 148 (40%) | 68 (36%) | 46 (32%) | ||
| Not reported | 32 (9%) | 4 (2%) | 7 (5%) | ||
| Transplant period | <.0001 | <.0001 | |||
| 2012-2014 | 64 (19%) | 105 (58%) | 67 (48%) | ||
| 2015-2017 | 272 (81%) | 77 (42%) | 73 (52%) | ||
| Variables . | Haplo-HSCT . | ≤5/8 HLA-matched UCB . | 6-8/8 HLA-matched UCB . | P value comparing haplo- to UCB . | |
|---|---|---|---|---|---|
| ≤5/8 . | 6-8/8 . | ||||
| Number of subjects | 375 | 188 | 145 | ||
| Age, y | <.001 | <.001 | |||
| ≤16 | 67 (18%) | 70 (37%) | 84 (58%) | ||
| 17 to 29 | 132 (35%) | 61 (32%) | 26 (18%) | ||
| 30 to 39 | 75 (20%) | 34 (18%) | 21 (15%) | ||
| 40 to 49 | 101 (27%) | 23 (12%) | 14 (10%) | ||
| Sex | .13 | .99 | |||
| Male | 202 (54%) | 114 (61%) | 78 (54%) | ||
| Female | 173 (46%) | 74 (39%) | 67 (46%) | ||
| Race | .84 | .06 | |||
| Caucasian | 235 (63%) | 113 (60%) | 100 (69%) | ||
| Non-Caucasian | 109 (29%) | 58 (31%) | 28 (19%) | ||
| Not reported | 31 (8%) | 17 (9%) | 17 (12%) | ||
| Performance score | <.0001 | .31 | |||
| 90 to 100 | 235 (63%) | 150 (80%) | 101 (70%) | ||
| ≤80 | 132 (35%) | 37 (20%) | 42 (29%) | ||
| Not reported | 8 (2%) | 1 (<1%) | 2 (1%) | ||
| Comorbidity index | .20 | <.0001 | |||
| ≤2 | 237 (63%) | 129 (69%) | 117 (81%) | ||
| ≥3 | 138 (37%) | 59 (31%) | 28 (19%) | ||
| Recipient CMV serostatus | .74 | .65 | |||
| Negative | 119 (32%) | 57 (30%) | 52 (36%) | ||
| Positive | 254 (68%) | 129 (69%) | 92 (63%) | ||
| Not reported | 2 (<1%) | 2 (1%) | 1 (<1%) | ||
| Disease | .003 | .002 | |||
| AML | 193 (52%) | 72 (38%) | 53 (37%) | ||
| ALL | 182 (49%) | 116 (62%) | 92 (63%) | ||
| Disease status | .02 | .002 | |||
| 1st CR | 233 (62%) | 98 (52%) | 68 (47%) | ||
| 2nd CR | 142 (38%) | 90 (48%) | 77 (53%) | ||
| Disease risk index | .17 | .003 | |||
| Low/intermediate | 280 (75%) | 130 (70%) | 89 (62%) | ||
| High/very high | 95 (25%) | 57 (30%) | 56 (39%) | ||
| Cytogenetic risk | .002 | .06 | |||
| Favorable | 79 (21%) | 61 (32%) | 44 (30%) | ||
| Intermediate | 116 (31%) | 55 (29%) | 48 (33%) | ||
| Poor | 148 (40%) | 68 (36%) | 46 (32%) | ||
| Not reported | 32 (9%) | 4 (2%) | 7 (5%) | ||
| Transplant period | <.0001 | <.0001 | |||
| 2012-2014 | 64 (19%) | 105 (58%) | 67 (48%) | ||
| 2015-2017 | 272 (81%) | 77 (42%) | 73 (52%) | ||